Type 1 Diabetes Mellitus Clinical Trial
Official title:
The Effect of Insulin-induced Hypoglycemia on Brain Lactate Accumulation and Regional Cerebral Blood Flow in Patients With Type 1 Diabetes Mellitus With and Without Hypoglycemia Unawareness and Non-diabetic Controls
Iatrogenic hypoglycemia is the most frequent acute complication of insulin therapy in people
with type 1 diabetes (T1DM). Recurrent hypoglycemic events initiate a process of
habituation, characterized by suppression of hypoglycemic symptoms and lead to hypoglycemia
unawareness, which in itself defines a particularly high risk of severe hypoglycemia. Recent
evidence suggest a pivotal role for increased brain lactate transport capacity in the
pathogenesis of hypoglycemia unawareness. However, there is uncertainty about the magnitude
of this effect and whether such excess brain lactate is oxidizes as a glucose-sparing
alternative energy source or acts as a metabolic regulator controlling brain glucose
metabolism, oxygen consumption and cerebral blood flow.
Objective: The primary objective of this study is to investigate the effect of hypoglycemia
on brain lactate accumulation and regional cerebral blood perfusion in humans. The secondary
objective is to assess whether this effect is a related to hypoglycemia unawareness or a
consequence of T1DM per se.
Hypothesis: The investigators hypothesize that hypoglycemia stimulates lactate transport
over the blood-brain barrier leading to cerebral lactate accumulation and that this lactate
accumulation is a function of prior hypoglycemic exposure frequency contributing to clinical
hypoglycemia unawareness. Furthermore, the investigators expect that this effect of
hypoglycemia on brain lactate accumulation is related to changes in cerebral blood flow
(CBF).
Status | Completed |
Enrollment | 21 |
Est. completion date | October 2015 |
Est. primary completion date | October 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion criteria for healthy subjects - Age: 18-50 years - Body-Mass Index: 18-30 kg/m2 - Blood pressure: <160/90 mmHg Inclusion criteria T1DM patients with normal hypoglycemic awareness - Diabetes duration = 1 year - Age: 18-50 years - Body-Mass Index: 18-30 kg/m2 - HbA1c: 42-75 mmol/mol (6-9%) - Outcome Clarke questionnaire: 0-1 - Blood pressure: <160/90 mmHg Inclusion criteria T1DM patients with hypoglycemia unawareness - Diabetes duration = 1 year - Age: 18-50 years - Body-Mass Index: 18-30 kg/m2 - HbA1c: 42-75 mmol/mol (6-9%) - Outcome Clarke questionnaire: >3 - Blood pressure: <160/90 mmHg Exclusion criteria for healthy subjects - Inability to provide informed consent - Presence of any medical condition that might interfere with the study protocol, such as brain injuries, epilepsy, a major cardiovascular disease event or anxiety disorders - Use of any medication, except for oral contraceptives - MR(I) contraindications (pregnancy, severe claustrophobia, metal parts in body) Exclusion criteria for all T1DM patients - Inability to provide informed consent - Presence of any other medical condition that might interfere with the study protocol, such as brain injuries, epilepsy, a major cardiovascular disease event, anxiety disorders, or complications of T1DM (including neuropathy and retinopathy) - Use of any other medication than insulin, except for oral contraceptives or stable thyroxine supplementation therapy - MR(I) contraindications (pregnancy, severe claustrophobia, metal parts in body) |
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Netherlands | Radboud umc | Nijmegen |
Lead Sponsor | Collaborator |
---|---|
Radboud University | Dutch Diabetes Research Foundation, European Foundation for the Study of Diabetes |
Netherlands,
Bergersen LH, Gjedde A. Is lactate a volume transmitter of metabolic states of the brain? Front Neuroenergetics. 2012 Mar 19;4:5. doi: 10.3389/fnene.2012.00005. eCollection 2012. — View Citation
De Feyter HM, Mason GF, Shulman GI, Rothman DL, Petersen KF. Increased brain lactate concentrations without increased lactate oxidation during hypoglycemia in type 1 diabetic individuals. Diabetes. 2013 Sep;62(9):3075-80. doi: 10.2337/db13-0313. Epub 2013 May 28. — View Citation
Herzog RI, Jiang L, Herman P, Zhao C, Sanganahalli BG, Mason GF, Hyder F, Rothman DL, Sherwin RS, Behar KL. Lactate preserves neuronal metabolism and function following antecedent recurrent hypoglycemia. J Clin Invest. 2013 May;123(5):1988-98. doi: 10.1172/JCI65105. Epub 2013 Apr 1. — View Citation
van de Ven KC, de Galan BE, van der Graaf M, Shestov AA, Henry PG, Tack CJ, Heerschap A. Effect of acute hypoglycemia on human cerebral glucose metabolism measured by ¹³C magnetic resonance spectroscopy. Diabetes. 2011 May;60(5):1467-73. doi: 10.2337/db10-1592. Epub 2011 Apr 4. — View Citation
van de Ven KC, Tack CJ, Heerschap A, van der Graaf M, de Galan BE. Patients with type 1 diabetes exhibit altered cerebral metabolism during hypoglycemia. J Clin Invest. 2013 Feb;123(2):623-9. doi: 10.1172/JCI62742. Epub 2013 Jan 9. — View Citation
van de Ven KC, van der Graaf M, Tack CJ, Heerschap A, de Galan BE. Steady-state brain glucose concentrations during hypoglycemia in healthy humans and patients with type 1 diabetes. Diabetes. 2012 Aug;61(8):1974-7. doi: 10.2337/db11-1778. Epub 2012 Jun 11. — View Citation
van de Ven KC, van der Graaf M, Tack CJ, Klomp DW, Heerschap A, de Galan BE. Optimized [1-(13)C]glucose infusion protocol for 13C magnetic resonance spectroscopy at 3T of human brain glucose metabolism under euglycemic and hypoglycemic conditions. J Neurosci Methods. 2010 Jan 30;186(1):68-71. doi: 10.1016/j.jneumeth.2009.10.025. Epub 2009 Nov 11. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Brain lactate concentration | Concentration brain lactate measured with 1H-MRS | during stable euglycemia and hypoglyemia | No |
Secondary | Plasma lactate levels | Concentration arterial plasma lactate | during stable euglycemia and hypoglyemia | No |
Secondary | Hormone response | during stable euglycemia and hypoglyemia | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 | |
Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A | |
Completed |
NCT02596204 -
Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring
|
N/A |